Go to content
- {{#headlines}}
- {{title}} {{/headlines}}
Profile
| Academic position | Full Professor |
|---|---|
| Research fields | Inorganic Molecular Chemistry,Pharmacy |
| Keywords | Medicinal Inorganic Chemistry, Bioinorganic Chemistry, Coordination Chemistry, Ligand Design, Radiopharmaceutical Chemistry |
Current contact address
| Country | Canada |
|---|---|
| City | Vancouver |
| Institution | University of British Columbia |
Host during sponsorship
| Prof. Dr. Bernt Krebs | Institut für Anorganische und Analytische Chemie, Universität Münster, Münster |
|---|---|
| Prof. Dr. Ekkehardt Hahn | Institut für Anorganische und Analytische Chemie, Universität Münster, Münster |
| Prof. Dr. Peter Comba | Anorganisch-Chemisches Institut, Ruprecht-Karls-Universität Heidelberg, Heidelberg |
| Start of initial sponsorship | 01/02/2000 |
Programme(s)
| 1999 | Humboldt Research Award Programme |
|---|
Nominator's project description
| Diabetis is an uncurable disease and its treatment requires the live-long non-oral applicaton of insuline. Professor Orvig has developed orally active drugs which might revolutionize the treatment of diabetis. As early as 1990 he and his team developed the complex bsi(maltolato)oxovanadium(V) (BMOV) which contains the food additive maltol, a ligand which can coordinate and faciliate the absorption of vanadium after the complex is taken orally. After preliminary studies with diabetic rats, BMOV became the model substance for orally active, vanadium containing insuline mimetic drugs. |
Publications (partial selection)
| 2014 | M. A. Telpoukhovskaia, C. Rodríguez-Rodríguez, J. F. Cawthray, L. E. Scott, B. D. G. Page, J. Alí-Torres, M. Sodupe, G. A. Bailey, B. O. Patrick, C. Orvig: 3-Hydroxy-4-pyridinone Derivatives as Metal Ion and Amyloid Binding Agents. In: Metallomics, 2014, 249-262 |
|---|---|
| 2014 | E. W. Price, B. M. Zeglis, J. S. Lewis, M. J. Adam, C. Orvig: H6phospa-trastuzumab: Bifunctional Methylenephosphonate-based Chelator with 89Zr, 111In and 177Lu. In: Dalton Trans., 2014, 119-131 |
| 2014 | Y. Mawani, C. Orvig: Improved Separation of the Curcuminoids, Syntheses of Their Rare Earth Complexes, and Studies of Potential Antiosteoporotic Activity. In: J. Inorg. Biochem., 2014, 52-58 |
| 2014 | E. W. Price, C. Orvig: Matching Chelators to Radiometals for Radiopharmaceuticals. In: Chem. Soc. Rev., 2014, 260-290 |
| 2014 | K. D. Mjos, C. Orvig: Metallodrugs in Medicinal Inorganic Chemistry. In: Chem. Rev., 2014, XXXX-YYYY |
| 2014 | M. A. Telpoukhovskaia, C. Rodríguez-Rodríguez, L. E. Scott, B. D. G. Page, B. O. Patrick, and C. Orvig: Synthesis, Characterization, and Cytotoxicity Studies of Cu(II), Zn(II), and Fe(III) Complexes of N-Derivatized 3-Hydroxy-4-pyridiones. In: J. Inorg. Biochem., 2014, 59-66 |
| 2013 | E. W. Price, B. M. Zeglis, J. F. Cawthray, C. F. Ramogida, N. Ramos, J. S. Lewis, M. J. Adam, C. Orvig: H4octapa-Trastuzumab: Versatile Acyclic Chelate System for 111In and 177Lu Imaging and Therapy. In: J. Am. Chem. Soc., 2013, 12707-12721 |